

NitricGen, Inc. Press Release June 5th 2013

NitricGen, Inc. is pleased to announce they were declared the winners of the 11th annual Wisconsin Governor's Business Plan Contest today in Middleton WI. There were over 300 entrants in this year's competition and the final round of judging was based on a 7 minute slide presentation made by each of the 13 finalists on June 4th with the winners announced at a lunch awards presentation.

NitricGen, Inc. is an early phase Medical Device Company based in Madison, WI. The company has designed a novel medical device "The eNO Generator" for producing gaseous nitric oxide to treat chronic diabetic foot ulcers. Nitric oxide is an amazing molecule which is naturally produced by the human body. Research over the last twenty years has shown it to be essential for controlling numerous biological functions including the successful healing of chronic wounds. The early researchers who discovered the role of nitric oxide in the human body went on to win the Noble Prize for Medicine in 1998. Patients with chronic diabetic foot ulcers face a debilitating condition with poor quality of life, open wounds that fail to heal, limited mobility with over 80,000 patients a year ultimately needing amputations. There is a clear need for a new more effective treatment such as nitric oxide therapy, for healing these chronic diabetic foot ulcers.

The eNO Generator is a small portable medical device that uses gas plasma to break down oxygen and nitrogen in room air and reform it into nitric oxide. The gas flow of nitric oxide is delivered to the patient's ulcer by a handheld applicator. Simply positioning the applicator over the diabetic foot ulcer and pressing "Start" is all that is required to deliver the 90 second per day treatment which is repeated daily for three weeks. This ease of use allows care givers to administer the nitric oxide treatment in the comfort of the patient's home. NitricGen, plans to conduct a clinical trial to prove the therapy is effective, and will use the clinical study for FDA approval and the start of sales. There are close to a million patients in the US suffering from chronic diabetic foot ulcers and when NitricGen is successful in bringing the nitric oxide therapy to market, it will relieve the suffering of those afflicted with this debilitating condition.

For additional information please email info@nitricgen.com